Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07094711 · ClinicalTrials.gov registry record · Phase 2
Safety, Immunogenicity, and Efficacy of Therapeutic Mycobacterium Bovis BCG (BOOST)
A Phase 2 study, sponsored by University of Virginia.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT07094711 is a Phase 2 study that is actively recruiting participants, run by University of Virginia. The registered enrollment target is 48 participants.
The verdict
NCT07094711, a Phase 2 study, is actively recruiting participants, sponsored by University of Virginia.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
The purpose of this study is to find out if the Mycobacterium bovis Bacillus Calmette Guerin (BCG) vaccine can be used safely to treat Mycobacterium avium complex (MAC) lung disease. Researchers will compare responses from patients with MAC lung disease after receiving an injection of BCG or placebo (a look-alike substance that contains no drug) Participants in the study: * Receive a BCG or placebo injection at UVA study center on Day 0 * Come to UVA study center on Day 60 * Come to UVA study center at the end of the study * Answer surveys and questionnaires about how you are doing * Have blood drawn 3 times, on injection day, day 60, and at end of study * Give the study team personal and demographic information * Discuss any new symptoms with the study team * Provide monthly sputum samples per usual care
Interventions
- BIOLOGICAL Mycobacterium bovis Bacillus Calmette Guerin (BCG) vaccine
- DRUG preservative-free saline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2026-04-27 |
| Est. Completion | 2028-12-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07094711
The ClinicalTrials.gov registry entry for NCT07094711 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Virginia, which has 449 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Mycobacterium bovis Bacillus Calmette Guerin (BCG) vaccine is the first listed.
NCT07094711 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07094711 about?
NCT07094711 is a clinical study titled "Safety, Immunogenicity, and Efficacy of Therapeutic Mycobacterium Bovis BCG (BOOST)". The purpose of this study is to find out if the Mycobacterium bovis Bacillus Calmette Guerin (BCG) vaccine can be used safely to treat Mycobacterium avium complex (MAC) lung disease. Researchers will compare responses from patients with MAC lung disease after receiving an injection of BCG or placeb...
What is the current status of trial NCT07094711?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2026-04-27. Estimated completion is 2028-12-30.
What interventions are being tested in trial NCT07094711?
The interventions under investigation include: Mycobacterium bovis Bacillus Calmette Guerin (BCG) vaccine (BIOLOGICAL), preservative-free saline (DRUG).
Who is sponsoring clinical trial NCT07094711?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.